科興製藥(688136.SH):人干擾素α2b噴霧劑臨牀試驗註冊申請獲受理
格隆匯8月14日丨科興製藥(688136.SH)公佈,近日,公司收到國家藥監局行政許可文書《受理通知書》,公司申報的“人干擾素α2b噴霧劑”臨牀試驗申請已獲得受理。
人干擾素α2b噴霧劑是公司自主研發的2類改良型新藥,是對已上市藥品劑型、給藥途徑進行優化,通過針對性局部給藥增加病灶部位藥物濃度,使用、攜帶方便,患者依從性好,具有明顯臨牀優勢。公司人干擾素α2b噴霧劑適應症為治療由病毒引起的初發或者複發性皮膚單純皰疹(口脣皰疹和生殖器皰疹)。
公司表示,人干擾素α2b噴霧劑的研發推進,將有助於優化公司產品結構,豐富產品管線,提升公司整體研發能力,增強公司長期盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.